Chinese General Practice ›› 2023, Vol. 26 ›› Issue (20): 2508-2512.DOI: 10.12114/j.issn.1007-9572.2022.0883
• Original Research • Previous Articles Next Articles
Received:
2022-09-08
Revised:
2023-01-19
Published:
2023-07-15
Online:
2023-01-06
Contact:
ZHENG Xiangqian
通讯作者:
郑向前
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0883
临床资料 | Aurora A低表达(n=28) | Aurora A高表达(n=62) | χ2值 | P值 |
---|---|---|---|---|
性别 | 4.147 | 0.042 | ||
男 | 8(28.6) | 32(51.6) | ||
女 | 20(71.4) | 30(48.4) | ||
年龄 | 3.223 | 0.073 | ||
<50岁 | 17(60.7) | 25(40.3) | ||
≥50岁 | 11(39.3) | 37(59.7) | ||
病灶位置a | 0.442 | 0.506 | ||
单侧 | 23(85.2) | 55(88.7) | ||
双侧 | 4(14.8) | 6(9.7) | ||
病灶数量 | 0.484 | 0.487 | ||
单发 | 21(96.4) | 42(50.8) | ||
多发 | 7(3.6) | 20(49.2) | ||
腺外侵犯b | 17.587 | <0.001 | ||
有 | 1(3.6) | 30(48.4) | ||
无 | 27(96.4) | 31(50.0) | ||
最大肿瘤直径 | 5.214 | 0.022 | ||
≤2 cm | 22(78.6) | 33(53.2) | ||
>2 cm | 6(21.4) | 29(46.8) | ||
T分期 | 16.540 | <0.001 | ||
T1/T2 | 25(80.8) | 27(53.8) | ||
T3/T4 | 3(19.2) | 35(46.2) | ||
N分期 | 6.184 | 0.045 | ||
N0 | 16(57.2) | 21(33.9) | ||
N1a | 6(21.4) | 11(17.7) | ||
N1b | 6(21.4) | 30(48.4) | ||
AJCC 8th临床分期 | 8.266 | 0.004 | ||
Ⅰ/Ⅱ | 16(50.8) | 15(3.8) | ||
Ⅲ/Ⅳ | 12(49.2) | 47(96.2) | ||
生化治愈 | 11.986 | 0.001 | ||
是 | 20(71.4) | 20(32.3) | ||
否 | 8(28.6) | 42(67.7) | ||
复发 | 4.199 | 0.040 | ||
是 | 2(7.1) | 16(25.8) | ||
否 | 26(92.9) | 46(74.2) |
Table 1 Comparison of clinical data between patients with different Aurora A expression levels
临床资料 | Aurora A低表达(n=28) | Aurora A高表达(n=62) | χ2值 | P值 |
---|---|---|---|---|
性别 | 4.147 | 0.042 | ||
男 | 8(28.6) | 32(51.6) | ||
女 | 20(71.4) | 30(48.4) | ||
年龄 | 3.223 | 0.073 | ||
<50岁 | 17(60.7) | 25(40.3) | ||
≥50岁 | 11(39.3) | 37(59.7) | ||
病灶位置a | 0.442 | 0.506 | ||
单侧 | 23(85.2) | 55(88.7) | ||
双侧 | 4(14.8) | 6(9.7) | ||
病灶数量 | 0.484 | 0.487 | ||
单发 | 21(96.4) | 42(50.8) | ||
多发 | 7(3.6) | 20(49.2) | ||
腺外侵犯b | 17.587 | <0.001 | ||
有 | 1(3.6) | 30(48.4) | ||
无 | 27(96.4) | 31(50.0) | ||
最大肿瘤直径 | 5.214 | 0.022 | ||
≤2 cm | 22(78.6) | 33(53.2) | ||
>2 cm | 6(21.4) | 29(46.8) | ||
T分期 | 16.540 | <0.001 | ||
T1/T2 | 25(80.8) | 27(53.8) | ||
T3/T4 | 3(19.2) | 35(46.2) | ||
N分期 | 6.184 | 0.045 | ||
N0 | 16(57.2) | 21(33.9) | ||
N1a | 6(21.4) | 11(17.7) | ||
N1b | 6(21.4) | 30(48.4) | ||
AJCC 8th临床分期 | 8.266 | 0.004 | ||
Ⅰ/Ⅱ | 16(50.8) | 15(3.8) | ||
Ⅲ/Ⅳ | 12(49.2) | 47(96.2) | ||
生化治愈 | 11.986 | 0.001 | ||
是 | 20(71.4) | 20(32.3) | ||
否 | 8(28.6) | 42(67.7) | ||
复发 | 4.199 | 0.040 | ||
是 | 2(7.1) | 16(25.8) | ||
否 | 26(92.9) | 46(74.2) |
临床资料 | 生化治愈患者(n=40) | 未生化治愈患者(n=50) | χ2值 | P值 |
---|---|---|---|---|
性别 | 4.160 | 0.041 | ||
男 | 13(32.5) | 27(54.0) | ||
女 | 27(67.5) | 23(46.0) | ||
年龄 | 0.502 | 0.479 | ||
<50岁 | 17(42.5) | 25(50.0) | ||
≥50岁 | 23(57.5) | 25(50.0) | ||
病灶位置a | 1.123 | 0.289 | ||
单侧 | 37(92.5) | 41(82.0) | ||
双侧 | 3(7.5) | 7(14.0) | ||
病灶数量 | 5.357 | 0.021 | ||
单发 | 33(82.5) | 30(60.0) | ||
多发 | 7(17.5) | 20(40.0) | ||
腺外侵犯b | 1.882 | 0.170 | ||
有 | 17(42.5) | 14(28.0) | ||
无 | 23(57.5) | 35(70.0) | ||
最大肿瘤直径 | 2.394 | 0.122 | ||
≤2 cm | 28(70.0) | 27(54.0) | ||
>2 cm | 12(30.0) | 23(46.0) | ||
T分期 | 14.575 | <0.001 | ||
T1/T2 | 32(80.0) | 20(40.0) | ||
T3/T4 | 8(20.0) | 30(60.0) | ||
N分期 | 6.264 | 0.044 | ||
N0 | 22(55.0) | 15(30.0) | ||
N1a | 7(17.5) | 10(20.0) | ||
N1b | 11(27.5) | 25(50.0) | ||
AJCC 8th临床分期 | 6.556 | 0.010 | ||
Ⅰ/Ⅱ | 20(50.0) | 12(24.0) | ||
Ⅲ/Ⅳ | 20(50.0) | 38(76.0) | ||
Aurora A表达情况 | 11.986 | 0.001 | ||
低表达 | 20(50.0) | 8(16.0) | ||
高表达 | 20(50.0) | 42(84.0) | ||
复发 | 2.531 | 0.112 | ||
是 | 35(87.5) | 37(74.0) | ||
否 | 5(12.5) | 13(26.0) |
Table 2 Comparison of clinical data between patients with different biochemical cured conditions
临床资料 | 生化治愈患者(n=40) | 未生化治愈患者(n=50) | χ2值 | P值 |
---|---|---|---|---|
性别 | 4.160 | 0.041 | ||
男 | 13(32.5) | 27(54.0) | ||
女 | 27(67.5) | 23(46.0) | ||
年龄 | 0.502 | 0.479 | ||
<50岁 | 17(42.5) | 25(50.0) | ||
≥50岁 | 23(57.5) | 25(50.0) | ||
病灶位置a | 1.123 | 0.289 | ||
单侧 | 37(92.5) | 41(82.0) | ||
双侧 | 3(7.5) | 7(14.0) | ||
病灶数量 | 5.357 | 0.021 | ||
单发 | 33(82.5) | 30(60.0) | ||
多发 | 7(17.5) | 20(40.0) | ||
腺外侵犯b | 1.882 | 0.170 | ||
有 | 17(42.5) | 14(28.0) | ||
无 | 23(57.5) | 35(70.0) | ||
最大肿瘤直径 | 2.394 | 0.122 | ||
≤2 cm | 28(70.0) | 27(54.0) | ||
>2 cm | 12(30.0) | 23(46.0) | ||
T分期 | 14.575 | <0.001 | ||
T1/T2 | 32(80.0) | 20(40.0) | ||
T3/T4 | 8(20.0) | 30(60.0) | ||
N分期 | 6.264 | 0.044 | ||
N0 | 22(55.0) | 15(30.0) | ||
N1a | 7(17.5) | 10(20.0) | ||
N1b | 11(27.5) | 25(50.0) | ||
AJCC 8th临床分期 | 6.556 | 0.010 | ||
Ⅰ/Ⅱ | 20(50.0) | 12(24.0) | ||
Ⅲ/Ⅳ | 20(50.0) | 38(76.0) | ||
Aurora A表达情况 | 11.986 | 0.001 | ||
低表达 | 20(50.0) | 8(16.0) | ||
高表达 | 20(50.0) | 42(84.0) | ||
复发 | 2.531 | 0.112 | ||
是 | 35(87.5) | 37(74.0) | ||
否 | 5(12.5) | 13(26.0) |
变量 | β | SE | Wald χ2值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
性别(以男性为参照) | ||||||
女性 | -0.529 | 0.538 | 0.966 | 0.326 | 0.59 | (0.21,1.69) |
病灶数量(以单发为参照) | ||||||
多发 | 1.156 | 0.583 | 3.928 | 0.047 | 3.18 | (1.01,9.97) |
T分期(以T1/T2为参照) | ||||||
T3/T4 | 1.305 | 0.640 | 4.154 | 0.042 | 3.69 | (1.05,12.93) |
N分期(以N0为参照) | ||||||
N1a | 1.141 | 1.066 | 1.147 | 0.284 | 3.13 | (0.39,25.30) |
N1b | 1.059 | 0.969 | 1.195 | 0.274 | 2.89 | (0.43,19.28) |
AJCC 8th临床分期(以Ⅰ/Ⅱ为参照) | ||||||
Ⅲ/Ⅳ | -0.900 | 1.088 | 0.685 | 0.408 | 0.41 | (0.05,3.43) |
Aurora-A是否高表达(以否为参照) | ||||||
是 | 1.171 | 0.564 | 4.310 | 0.038 | 3.22 | (1.07,9.74) |
Table 3 Multivariate Logistic regression multivariate analysis of influencing factors for biochemical cure in MTC patients
变量 | β | SE | Wald χ2值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
性别(以男性为参照) | ||||||
女性 | -0.529 | 0.538 | 0.966 | 0.326 | 0.59 | (0.21,1.69) |
病灶数量(以单发为参照) | ||||||
多发 | 1.156 | 0.583 | 3.928 | 0.047 | 3.18 | (1.01,9.97) |
T分期(以T1/T2为参照) | ||||||
T3/T4 | 1.305 | 0.640 | 4.154 | 0.042 | 3.69 | (1.05,12.93) |
N分期(以N0为参照) | ||||||
N1a | 1.141 | 1.066 | 1.147 | 0.284 | 3.13 | (0.39,25.30) |
N1b | 1.059 | 0.969 | 1.195 | 0.274 | 2.89 | (0.43,19.28) |
AJCC 8th临床分期(以Ⅰ/Ⅱ为参照) | ||||||
Ⅲ/Ⅳ | -0.900 | 1.088 | 0.685 | 0.408 | 0.41 | (0.05,3.43) |
Aurora-A是否高表达(以否为参照) | ||||||
是 | 1.171 | 0.564 | 4.310 | 0.038 | 3.22 | (1.07,9.74) |
[1] |
|
[2] |
|
[3] |
|
[4] |
陶子夏,丁政,邓先兆,等. 甲状腺髓样癌术后复发的外科诊治策略[J]. 临床外科杂志,2022,30(3):213-215. DOI:10.3969/j.issn.1005-6483.2022.03.005.
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
张诠,杨传盛,郭朱明,等. 甲状腺髓样癌预后影响因素分析[J]. 中华耳鼻咽喉头颈外科杂志,2008,43(12):939-943. DOI:10.3321/j.issn:1673-0860.2008.12.015.
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
中国抗癌协会甲状腺癌专业委员会(CATO). 甲状腺癌血清标志物临床应用专家共识(2017版)[J]. 中国肿瘤临床,2018,45(1):7-13. DOI:10.3969/j.issn.1000-8179.2018.01.265.
|
[24] |
|
[25] |
|
[26] |
朱玉懿,张琬琛,李秀萍,等. 甲状腺髓样癌生化复发预后的Meta分析及预测术后结构复发的降钙素最佳临界值确定[J]. 肿瘤研究与临床,2022,34(5):375-381.
|
[27] |
|
[28] |
|
[1] | ZHANG Aili, HOU Qiqi, HAN Quanle, ZHANG Boheng, ZHANG Jiawei, CAO Hongxia, ZHANG Chao, CHEN Shuohua, WU Shouling, LI Kangbo. Correlation between Atrial Fibrillation and the Risk of New-onset Chronic Kidney Disease in Northern Chinese Population [J]. Chinese General Practice, 2023, 26(36): 4521-4526. |
[2] | XUE Chongxiang, LU Xingyu, LIU Zhening, DONG Huijing, ZHENG Yumin, CUI Huijuan. Dynamic Monitoring of Gene Changes and Its Prognostic Value in Lung Cancer Patients [J]. Chinese General Practice, 2023, 26(36): 4527-4534. |
[3] | BAI Haiwei, MI Xiaokun, LIU Qingrui, ZHU Lin, WANG Yingnan, LIU Junyan, HAN Ying. Predictive Value of Serum Uric Acid in Perioperative Acute Ischemic Stroke in Patients with Non-small Cell Lung Cancer [J]. Chinese General Practice, 2023, 26(36): 4545-4551. |
[4] | CHU Xiaojing, LI Jun, FU Yanqin, LIU Danqing, LIU Aiping, ZHANG Yuanyuan. Effect of Human Body Composition and Serum Biochemical Indicators on the Accuracy of Flash Glucose Monitoring System [J]. Chinese General Practice, 2023, 26(35): 4433-4438. |
[5] | CUI Xiaona, FENG Ruixia, HAN Yupeng, ZHOU Yaoyao, LIU Xiaojun, LI Jianchao. A Comparative Study on Clinical Effects of Combined Auxiliary Sequence of VA-ECMO and IABP on Acute Myocardial Infarction Complicated with Cardiogenic Shock [J]. Chinese General Practice, 2023, 26(35): 4439-4445. |
[6] | XIE Xuemei, GAO Jing, BAI Dingxi, LU Xianying, HE Jiali, LI Yue. Current Status of Polypharmacy in the Elderly and Its Influencing Factors: a Meta-analysis [J]. Chinese General Practice, 2023, 26(35): 4394-4403. |
[7] | WANG Yue, CHEN Qing, LIU Lurong. Detection Rate of Depression and Its Influencing Factors in Chinese Elderly: a Meta-analysis [J]. Chinese General Practice, 2023, 26(34): 4329-4335. |
[8] | HAO Aihua, ZENG Weilin, LI Guanhai, XIA Yinghua, CHEN Liang. Current Situation of the Construction of Family Doctor Team: an Investigation Based on the Perspective of General Practitioners [J]. Chinese General Practice, 2023, 26(34): 4261-4268. |
[9] | LI Dianjiang, PAN Enchun, SUN Zhongming, WEN Jinbo, WANG Miaomiao, WU Ming, SHEN Chong. The Current Status and Influencing Factors of Clinical Inertia in Type 2 Diabetes Patients in Community [J]. Chinese General Practice, 2023, 26(34): 4296-4301. |
[10] | QIN Fengyin, ZHANG Qishan, LAI Jinjia, HUANG Yimin, HAN Guoyin, SUN Xinglan, WANG Fen, TAN Yibing. Current Status and Influencing Factors of the Intention to Screen for High-risk Stroke among Community Residents in Guangdong [J]. Chinese General Practice, 2023, 26(34): 4283-4289. |
[11] | WANG Lina, GAO Pengfei, CAO Fan, GE Ying, YAN Wei, HE Daikun. Analysis of the Prevalence and Influencing Factors of Non-alcoholic Fatty Liver Disease in Different Gender Groups [J]. Chinese General Practice, 2023, 26(33): 4143-4151. |
[12] | ZHOU Yuyu, GAO Chuan, CUI Puan, WANG Yaping, HE Zhong. Influencing Factors of Shared Decision Making between Doctors and Patients in Menopausal Hormone Therapy in Patients with Menopausal Syndrome [J]. Chinese General Practice, 2023, 26(33): 4181-4186. |
[13] | ZHANG Siyu, ZHOU Yuqiu, DU Xiaohui, WANG Zhengjun. Advances in Duration of Untreated Psychosis and Its Early Intervention [J]. Chinese General Practice, 2023, 26(33): 4110-4117. |
[14] | ZHANG Jin, DING Zhiguo, QI Shuo, LI Ying, LI Weiqiang, ZHANG Yuanyuan, ZHOU Tong. Relationship between Serum Thyroid Hormone Levels and Prognosis during Hospitalization in Heart Failure Patients [J]. Chinese General Practice, 2023, 26(33): 4125-4129. |
[15] | LIANG Xuan, NA Feiyang, QIN Mengyao, YANG Hui, GUO Li, GUO Qi, REN Lei, CHEN De, LIU Donghai, ZHANG Rongfang. Clinical Characteristics and Influencing Factors of Bronchial Asthma Combined with Obstructive Sleep Apnea-hypopnea Syndrome in Children [J]. Chinese General Practice, 2023, 26(33): 4225-4230. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||